Barrett's Esophagus: Pathogenesis, Treatment, and Prevention

Gastrointestinal Endoscopy Clinics of North America

Volumn 18, Issue 3, 2008, Pages 495-512

  Badreddine, Rami J ^a   Wang, Kenneth K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BODY MASS; CANCER GRADING; CAUTERIZATION; CHEMOPROPHYLAXIS; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; ELECTROCOAGULATION; ENDOSCOPIC THERAPY; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENE EXPRESSION; HEREDITY; HUMAN; LOWER ESOPHAGUS SPHINCTER; NONHUMAN; OBESITY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; STOMACH FUNDOPLICATION; SURGICAL TECHNIQUE; WAIST CIRCUMFERENCE; YAG LASER;

BARRETT ESOPHAGUS; ESOPHAGOSCOPY; HUMANS; PROGNOSIS;

EID: 47949125715     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2008.05.005     Document Type: Review

References (74)

1. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 2 (2005) 142-146
2. Cameron A.J., Zinsmeister A.R., Ballard D.J., et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99 4 (1990) 918-922
3. Cameron A.J., and Lomboy C.T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103 4 (1992) 1241-1245
4. Nandurkar S., and Talley N.J. Barrett's esophagus: the long and the short of it. Am J Gastroenterol 94 1 (1999) 30-40
5. Johnston M.H., Hammond A.S., Laskin W., et al. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol 91 8 (1996) 1507-1511
6. Playford R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 55 4 (2006) 442
7. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 131 5 (2006) 1392-1399
8. Gillen P., Keeling P., Byrne P.J., et al. Experimental columnar metaplasia in the canine oesophagus. Br J Surg 75 2 (1988) 113-115
9. Fitzgerald R.C., Omary M.B., and Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98 9 (1996) 2120-2128
10. Champion G., Richter J.E., Vaezi M.F., et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 107 3 (1994) 747-754
11. Singh P., Taylor R.H., and Colin-Jones D.G. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 89 3 (1994) 349-356
12. Coenraad M., Masclee A.A., Straathof J.W., et al. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?. Am J Gastroenterol 93 7 (1998) 1068-1072
13. Fass R., Hell R.W., Garewal H.S., et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 48 3 (2001) 310-313
14. Loughney T., Maydonovitch C.L., and Wong R.K. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol 93 6 (1998) 916-919
15. Fletcher J., Wirz A., Young J., et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 121 4 (2001) 775-783
16. Fletcher J., Wirz A., Henry E., et al. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 53 2 (2004) 168-173
17. Hirschowitz B.I. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 41 7 (1996) 1384-1391
18. Iijima K., Henry E., Moriya A., et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122 5 (2002) 1248-1257
19. Kauer W.K., Peters J.H., DeMeester T.R., et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 122 5 (1997) 874-881
20. Kauer W.K., Peters J.H., DeMeester T.R., et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 222 4 (1995) 525-531 [discussion: 531-3]
21. Sokol R.J., Winklhofer-Roob B.M., Devereaux M.W., et al. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 109 4 (1995) 1249-1256
22. Payne C.M., Crowley-Weber C.L., Dvorak K., et al. Mitochondrial perturbation attenuates bile acid-induced cytotoxicity. Cell Biol Toxicol 21 5-6 (2005) 215-231
23. Bernstein H., Bernstein C., Payne C.M., et al. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 589 1 (2005) 47-65
24. Washo-Stultz D., Crowley-Weber C.L., Dvorakova K., et al. Role of mitochondrial complexes I and II, reactive oxygen species and arachidonic acid metabolism in deoxycholate-induced apoptosis. Cancer Lett 177 2 (2002) 129-144
25. Bernstein H., Payne C.M., Bernstein C., et al. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol Lett 108 1 (1999) 37-46
26. Venturi M., Hambly R.J., Glinghammar B., et al. Genotoxic activity in human faecal water and the role of bile acids: a study using the alkaline comet assay. Carcinogenesis 18 12 (1997) 2353-2359
27. Nehra D., Howell P., Williams C.P., et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44 5 (1999) 598-602
28. Dvorak K., Payne C.M., Chavarria M., et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 56 6 (2007) 763-771
29. van Baal J.W., Milano F., Rygiel A.M., et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129 4 (2005) 1274-1281
30. Milano F., van Baal J.W., Buttar N.S., et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132 7 (2007) 2412-2421
31. Kaiser S., Schirmacher P., Philipp A., et al. Induction of bone morphogenetic protein-6 in skin wounds. Delayed reepitheliazation and scar formation in BMP-6 overexpressing transgenic mice. J Invest Dermatol 111 6 (1998) 1145-1152
32. Frank S., Madlener M., and Werner S. Transforming growth factors beta1, beta2, and beta3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 271 17 (1996) 10188-10193
33. Rosendahl A., Pardali E., Speletas M., et al. Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation. Am J Respir Cell Mol Biol 27 2 (2002) 160-169
34. Moons L.M., Siersema P.D., Kuipers E.J., et al. A pro-inflammatory IL-10/1L-12 gene profile is associated with an increased risk for developing Barrett's esophagus. [abstract]. Gastroenterology 130 4 Suppl 2 (2006) A76
35. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 133 1 (2007) 34-41 quiz 311
36. Sampliner R.E., Garewal H.S., Fennerty M.B., et al. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 35 1 (1990) 93-96
37. Peters F.T., Ganesh S., Kuipers E.J., et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 45 4 (1999) 489-494
38. Sampliner R.E. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 89 10 (1994) 1844-1848
39. Malesci A., Savarino V., Zentilin P., et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 44 6 (1996) 700-705
40. Cooper B.T., Neumann C.S., Cox M.A., et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 12 9 (1998) 893-897
41. Wilkinson S.P., Biddlestone L., Gore S., et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 13 9 (1999) 1205-1209
42. Sharma P., Morales T.G., Bhattacharyya A., et al. Squamous islands in Barrett's esophagus: what lies underneath?. Am J Gastroenterol 93 3 (1998) 332-335
43. Katzka D.A., and Castell D.O. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 89 7 (1994) 989-991
44. Sharma P., Sampliner R.E., and Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 92 4 (1997) 582-585
45. Fass R., Sampliner R.E., Malagon I.B., et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 14 5 (2000) 597-602
46. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 11 (1999) 825-831
47. Feagins L.A., Zhang H.Y., Hormi-Carver K., et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 102 1 (2007) 10-20
48. Ouatu-Lascar R., and Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 93 5 (1998) 711-716
49. Srinivasan R., Katz P.O., Ramakrishnan A., et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 15 4 (2001) 519-524
50. McDonald M.L., Trastek V.F., Allen M.S., et al. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance?. J Thorac Cardiovasc Surg 111 6 (1996) 1135-1138 [discussion: 1139-40]
51. Yau P., Watson D.I., Devitt P.G., et al. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch Surg 135 7 (2000) 801-805
52. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285 18 (2001) 2331-2338
53. Sampliner R.E., Faigel D., Fennerty M.B., et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc 53 6 (2001) 554-558
54. Pereira-Lima J.C., Busnello J.V., Saul C., et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 95 7 (2000) 1661-1668
55. Van Laethem J.L., Cremer M., Peny M.O., et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 43 6 (1998) 747-751
56. Schulz H., Miehlke S., Antos D., et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 51 6 (2000) 659-663
57. Byrne J.P., Armstrong G.R., and Attwood S.E. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 93 10 (1998) 1810-1815
58. Morris C.D., Byrne J.P., Armstrong G.R., et al. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 88 10 (2001) 1357-1362
59. Shand A., Dallal H., Palmer K., et al. Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 48 4 (2001) 580-581
60. Van Laethem J.L., Peny M.O., Salmon I., et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 46 4 (2000) 574-577
61. Michopoulos S., Tsibouris P., Bouzakis H., et al. Complete regression of Barrett's esophagus with heat probe thermocoagulation: mid-term results. Gastrointest Endosc 50 2 (1999) 165-172
62. Sharma V.K., Wang K.K., Overholt B.F., et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 65 2 (2007) 185-195
63. Overholt B.F., Panjehpour M., and Haydek J.M. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 49 1 (1999) 1-7
64. Prasad G.A., Wang K.K., Buttar N.S., et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 132 4 (2007) 1226-1233
65. Prasad G.A., Wang K.K., Buttar N.S., et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 65 1 (2007) 60-66
66. Overholt B.F., Lightdale C.J., Wang K.K., et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62 4 (2005) 488-498
67. Ell C., May A., Gossner L., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118 4 (2000) 670-677
68. Pacifico R.J., Wang K.K., Wongkeesong L.M., et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 1 4 (2003) 252-257
69. Shimizu Y., Tsukagoshi H., Fujita M., et al. Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc 56 3 (2002) 387-390
70. Prasad G.A., Buttar N.S., Wongkeesong L.M., et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 102 (2007) 2380-2386
71. Johnston M.H., Eastone J.A., Horwhat J.D., et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 62 6 (2005) 842-848
72. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 118 3 (2000) 487-496
73. Morris C.D., Armstrong G.R., Bigley G., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96 4 (2001) 990-996
74. Heath E.I., Canto M.I., Piantadosi S., et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99 7 (2007) 545-557